We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-21.25%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$791M
AUM Growth
+$150M
Cap. Flow
+$346M
Cap. Flow %
43.72%
Top 10 Hldgs %
55.59%
Holding
46
New
16
Increased
14
Reduced
9
Closed
6

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$44.2M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$42.8M
3
PBYI icon
Puma Biotechnology
PBYI
+$41.4M
4
ZGNX
Zogenix, Inc.
ZGNX
+$40.9M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$30.2M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$36.8M
2
ECYT
Endocyte, Inc. Common Stock
ECYT
+$28.5M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$20M
4
VYGR icon
Voyager Therapeutics
VYGR
+$13.3M
5
ARGX icon
argenx
ARGX
+$9.82M

Sector Composition

Rank Sector Weight
1 Healthcare 86.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
1
BioCryst Pharmaceuticals
BCRX
$2.28B
$61.5M 7.77%
7,622,256
-356,019
-4% -$2.77M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$1.82B
$49.3M 6.23%
5,567,348
+2,071,008
+59% +$20M
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
$48.4M 6.12%
+1,180,000
New +$44.2M
XLRN
4
DELISTED
Acceleron Pharma
XLRN
$45.1M 5.71%
1,036,575
+118,808
+13% +$5.94M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.43B
$44.5M 5.63%
2,752,256
+1,556,158
+130% +$30.2M
PTCT icon
6
PTC Therapeutics
PTCT
$5.64B
$42M 5.31%
1,225,000
+507,542
+71% +$18.2M
KURA icon
7
Kura Oncology
KURA
$800M
$38.9M 4.91%
2,769,527
+650,421
+31% +$8.62M
UTHR icon
8
United Therapeutics
UTHR
$25.8B
$38.2M 4.83%
350,800
+50,800
+17% +$5.89M
ZGNX
9
DELISTED
Zogenix, Inc.
ZGNX
$36.5M 4.61%
+1,000,000
New +$40.9M
BOLD
10
DELISTED
Audentes Therapeutics, Inc
BOLD
$35.3M 4.47%
+1,657,873
New +$42.8M
VRTX icon
11
PUT
Vertex Pharmaceuticals
VRTX
$121B
$33.1M 4.19%
+200,000
New +$34.7M
PBYI icon
12
Puma Biotechnology
PBYI
$404M
$28.1M 3.55%
+1,379,700
New +$41.4M
ARRY
13
DELISTED
Array Biopharma Inc
ARRY
$26.4M 3.33%
+1,850,000
New +$28.1M
ONCE
14
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$24.7M 3.12%
630,600
+237,453
+60% +$10.3M
FPRX
15
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$22.3M 2.82%
2,398,409
+750,656
+46% +$8.93M
ICPT
16
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$20.2M 2.55%
+200,000
New +$20.7M
CYTK icon
17
Cytokinetics
CYTK
$10.5B
$20.1M 2.53%
3,173,288
+993,600
+46% +$7.29M
LRMR icon
18
Larimar Therapeutics
LRMR
$397M
$17.8M 2.25%
299,866
+17,251
+6% +$1.7M
FOMX
19
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$14.5M 1.84%
4,047,561
+17,293
+0.4% +$75.2K
SVRA icon
20
Savara
SVRA
$1.12B
$13.8M 1.74%
1,819,195
-423,889
-19% -$3.81M
TGTX icon
21
TG Therapeutics
TGTX
$7.96B
$12.3M 1.55%
3,000,000
+1,050,000
+54% +$5.22M
RVLP
22
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$11.6M 1.47%
+1,500,000
New +$12M
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
$11.2M 1.41%
+1,418,489
New +$13.5M
TPST icon
24
Tempest Therapeutics
TPST
$13.7M
$10.2M 1.29%
+6,606
New +$13.6M
KRYS icon
25
Krystal Biotech
KRYS
$10.1B
$10.2M 1.29%
+492,100
New +$10.3M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Great Point Partners held 46 positions worth $791M, up 23% from $642M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Great Point Partners deployed $346M of net new capital in Q4 2018, opening 16 new positions and adding to 14 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 1,180,000 shares worth $48.4M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $20M trimmed.

  • Great Point Partners's largest Q4 2018 buy was Global Blood Therapeutics, Inc.: 1,180,000 shares worth $48.4M.
  • Great Point Partners added most to Acadia Pharmaceuticals in Q4 2018, an estimated $30.2M increase.
  • Great Point Partners's biggest Q4 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $20M.
  • Great Point Partners fully exited Exelixis in Q4 2018, selling an estimated $36.8M.
  • Great Point Partners's ten largest holdings make up 56% of its $791M portfolio in Q4 2018.
  • Great Point Partners opened 16 new positions and closed 6 in Q4 2018.
  • Great Point Partners's portfolio value rose 23% quarter-over-quarter to $791M.

Based on Great Point Partners's 13F filing for Q4 2018, filed 15 Feb 2019.